Dr. Randall A. Oyer, founding executive medical director of the 11-year-old Ann B. Barshinger Cancer Institute, is retiring.

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 mo ...

At the four-day-long event, representatives from pediatric cancer awareness foundations travel to Capitol Hill to speak to ...

Ann Arbor-based Michigan Medicine will establish the Weiser Family Center for Breast Cancer after receiving a $25 million gift from the Weiser Charitable Foundation.

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® ...

University of Michigan Health-West has named a new chief medical officer.  Dr. Clifford Cho was appointed CMO of University of Michigan Health-West in May 2024.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

He and his wife Ann met while singing in the Lakeshore Chorale in Sheboygan ... We would like to thank Dr. Sam Lubner and Keith’s oncology team at the UW Health Carbone Center for their incredible ...

Cairn Surgical announces the first commercial use of its Breast Cancer Locator (BCL) System designed to improve the accuracy ...